SYROS PHARMACEUTICALS INC by Syros Pharmaceuticals, Inc. Financials - Benzinga

SYROS PHARMACEUTICALS INC by Syros Pharmaceuticals, Inc.

SYRSOTCEM

Trade with Public

Trade with Public

$0.1172

At close: Mar 28, 5:00 PM EST

Overview News Earnings Forecast Events Price TargetsFinancialsSentiment Ownership Compare

SYROS PHARMACEUTICALS INC by Syros Pharmaceuticals, Inc. Financials

SYROS PHARMACEUTICALS INC by Syros Pharmaceuticals, Inc. (SYRS) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

Dow Dips Over 200 Points; US Industrial Production Increases More than Expected

Avi Kapoor

US Stocks Mixed; Kohl's Shares Plunge After Q4 Results

Avi Kapoor

S&P 500 Tops 6,000; Rumble Shares Slide After Q3 Results

Avi Kapoor

Dow Jumps Over 150 Points; CyberArk Posts Upbeat Earnings

Avi Kapoor

US Stocks Mixed; Inflation Rate Increases In October

Avi Kapoor

PRO
Syros Pharmaceuticals Q3 2024 GAAP EPS $(0.16) Beats $(0.72) Estimate. Cash and Equivalents Of $60.4M

Syros Pharmaceuticals (NASDAQ:SYRS) reported quarterly losses of $(0.16) per share which beat the analyst consensus estimate of $(0.72) by 77.78 percent. This is a 88.81 percent increase over losses of $(1.43) per share

Benzinga Newsdesk